Analysis of the occurrence of interstitial pneumonia and its related factors in patients with diffuse large B-cell lymphoma after the treatment of CHOP-like regimens containing liposomal doxorubicin
10.3760/cma.j.cn115355-20210305-00116
- VernacularTitle:弥漫大B细胞淋巴瘤患者含脂质体多柔比星CHOP样方案治疗后间质性肺炎发生情况及相关因素分析
- Author:
Juan PAN
1
;
Shujuan WEN
;
Shan LI
;
Xiao LIANG
;
Shune YANG
Author Information
1. 新疆医科大学附属肿瘤医院淋巴瘤科，乌鲁木齐 830011
- Keywords:
Lymphoma, non-Hodgkin;
Lymphoma, large B-cell, diffuse;
Doxorubicin;
Liposomes;
Lung diseases, interstitial;
Risk factors
- From:
Cancer Research and Clinic
2021;33(7):527-532
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the occurrence and risk factors of interstitial pneumonia (IP) in patients with diffuse large B-cell lymphoma (DLBCL) after the treatment of CHOP-like regimens containing liposomal doxorubicin.Methods:The clinical data of 145 newly diagnosed and newly treated DLBCL patients who were admitted to the Affiliated Tumor Hospital of Xinjiang Medical University from January 2013 to June 2020 were retrospectively analyzed, of which 73 cases were treated with RCDOP regimen containing liposomal doxorubicin, and 72 cases were treated with RCHOP regimen. The incidence of IP was compared between the two groups, and the risk factors of IP were analyzed by multivariate logistic regression.Results:In 145 patients, 34 patients (23.4%) developed IP; most cases of IP occurred during 3 to 5 cycles of chemotherapy, accounting for 79.4% (27/34); when IP occurred, the median cycles of chemotherapy was 4 cycles. The incidence of IP in RCDOP regimen group and RCHOP regimen group were 31.5% (23/73) and 15.3% (11/72), and the difference was statistically significant ( χ2 = 5.319, P < 0.05). Multivariate logistic regression analysis showed that the application of liposomal doxorubicin ( OR = 2.416, 95% CI 1.059-5.509, P = 0.036) and age ≥60 years old ( OR = 2.505, 95% CI 1.127-5.567, P = 0.024) were independent risk factors for the occurrence of IP. Conclusions:The application of liposomal doxorubicin is a risk factor for the occurrence of IP in DLBCL patients. The prevention and monitoring of IP should be strengthened after 4 cycles of treatment with RCDOP regimen, especially for patient ≥ 60 years of age.
